Malta - English - Medicines Authority

adamed sp. z.o.o. pieńków 149, 05-152 czosnów, poland - solifenacin succinate - film-coated tablet - solifenacin succinate 5 mg - urologicals

Malta - English - Medicines Authority

adamed sp. z.o.o. pieńków 149, 05-152 czosnów, poland - solifenacin succinate - film-coated tablet - solifenacin succinate 10 mg - urologicals

Malta - English - Medicines Authority

stada arzneimittel ag stadastraße 2-18, 61118 bad vilbel, germany - solifenacin succinate - film-coated tablet - solifenacin succinate 5 mg - urologicals

Malta - English - Medicines Authority

stada arzneimittel ag stadastraße 2-18, 61118 bad vilbel, germany - solifenacin succinate - film-coated tablet - solifenacin succinate 10 mg - urologicals

Malta - English - Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - solifenacin succinate - film-coated tablet - solifenacin succinate 5 mg - urologicals

Malta - English - Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - solifenacin succinate - film-coated tablet - solifenacin succinate 10 mg - urologicals

United States - English - NLM (National Library of Medicine)

scleracare, llc - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - • for the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites or minor skin irritations.

United States - English - NLM (National Library of Medicine)

cipla usa inc. - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate tablets are contraindicated in patients: -   with urinary retention [see warnings and precautions (5.2)] , -   with gastric retention [see warnings and precautions (5.3)] , -   with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5)] , and -   who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2)] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice